Mark Bussard is a vice president of T. Rowe Price Group, Inc., and T. Rowe Price Associates, Inc. He is a research analyst in the Equity Division following the biotechnology and medical technology sectors of the health care industry. Mark is a vice president and Investment Advisory Committee member of the Health Sciences Fund, the New Horizons Fund, the Blue Chip Growth Fund, and the Growth and Income Fund. Prior to joining T. Rowe Price in 2005, Mark was a co-founder of Rivanna Pharmaceuticals, an early stage biotechnology firm. He earned his medical degree at the University of Virginia, where he was also a resident in general surgery and was elected into the Alpha Omega Alpha medical honor society. Mark also earned a B.A. in chemistry and biology from Williams College and an M.B.A from the Darden Graduate School of Business Administration, where he was designated a William Michael Shermet Scholar.
